Browse > Article

The Effects of Fluconazole on Chronic Oral Candidiasis Refractory to Nystatin: Case Report  

Lee, Eun-Jin (Dept. of Oral Medicine & Oral Diagnosis, School of Dentistry, Seoul National University)
Park, Won-Kyu (Dept. of Oral Medicine & Oral Diagnosis, School of Dentistry, Seoul National University)
Kho, Hong-Seop (Dept. of Oral Medicine & Oral Diagnosis, School of Dentistry, Seoul National University)
Publication Information
Journal of Oral Medicine and Pain / v.33, no.1, 2008 , pp. 27-33 More about this Journal
Abstract
Candidiasis, an opportunistic infectious condition caused by the genus Candida, is the most common oral fungal infection in humans. The diagnosis of oral candidiasis can often be made based on recognition of its clinical pattern, but at times there is difficulty in making a clinical diagnosis because of its various manifestations. Several antifungal medications have been developed for managing fungal infections. Despite the availability of several effective antimycotics for the treatment of oral candidiasis, failure of therapy is not uncommon due to the unique environment of the oral cavity, where the flushing effect of saliva and the cleaning action of the oral musculature tend to reduce the drug concentration to sub-therapeutic levels. In this case report, we present two patients diagnosed with chronic hyperplastic candidiasis and median rhomboid glossitis, which are known as rare forms of candidiasis. In both cases, there was a significant reduction of clinical signs and symptoms when fluconazole was prescribed after the failure of initial nystatin therapy.
Keywords
Candidiasis; Fluconazole; Nystatin;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Scully C, Oral and maxillofacial medicine. 1st ed., Wright, 2004, Elsevier, pp.252-268
2 Blomgren J, Berggren U, Jontell M. Fluconazole versus nystatin in the treatment of oral candidosis. Acta Odontol Scand 1998;56:202-205   DOI
3 Mycek MJ, Harvey RA, Champe PC. Lippincott's illustrated reviews : pharmacology. 2nd ed., Hampton, 2000, Lippincott Williams & Wilkins, pp.337-344
4 Francois IE, Aerts AM, Cammue BP, Thevissen K. Currently used antimycotics: spectrum, mode of action and resistance occurrence. Curr Drug Targets 2005;6:895-907   DOI   ScienceOn
5 Ellepola AN, Samaranayake LP. Oral candidal infections and antimycotics. Crit Rev Oral Biol Med 2000;11:172-198   DOI
6 Neville BW, Damm DD, Allen CM, Bouquot JE. Oral & maxillofacial pathology. 2nd ed., Philadelphia, 2002, WB Saunders Co., pp.189-197
7 Force RW, Nahata MC. Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. Ann Pharmacother 1995;29:10-15   DOI
8 McCullough MJ, Savage NW. Oral candidosis and the therapeutic use of antifungal agents in dentistry. Aust Dent J 2005;50:S36-39   DOI   ScienceOn
9 Darwazeh AMG, Lamey PJ, Lewis MAO, Samaranayake LP. Systemic fluconazole therapy and in vitro adhesion of Candida albicans to human buccal epithelial cells, J Oral Pathol Med 1991;20:17-19   DOI   ScienceOn
10 Shin ES, Chung SC, Kim YK, Lee SW, Kho HS. The relationship between oral Candida carriage and the secretor status of blood group antigens in saliva. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;96:48-53   DOI   ScienceOn
11 Samaranayake LP, Ferguson MM. Delivery of antifungal agents to the oral cavity. Adv Drug Deliv Rev 1994;13:161-179   DOI   ScienceOn